{
    "root": "85ffdba9-4ecd-4a76-b91b-52eeb3f3acc3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZTALMY",
    "value": "20250424",
    "ingredients": [
        {
            "name": "ganaxolone",
            "code": "98WI44OHIQ"
        },
        {
            "name": "anhydrous citric acid",
            "code": "XF417D3PSL"
        },
        {
            "name": "hypromellose, unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "methylparaben",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "polyvinyl alcohol, unspecified",
            "code": "532B59J990"
        },
        {
            "name": "propylparaben",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        },
        {
            "name": "sodium benzoate",
            "code": "OJ245FE5EU"
        },
        {
            "name": "sodium citrate, unspecified form",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "sodium lauryl sulfate",
            "code": "368GB5141J"
        },
        {
            "name": "sucralose",
            "code": "96K6UQ3ZD4"
        }
    ],
    "indications": "ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.",
    "contraindications": "Administer ZTALMY orally three times daily with food. ( 2.1 ) Titrate ZTALMY gradually according to the recommended schedules. See full prescribing information. ( 2.1 ) Dosage for patients weighing 28 kg or less ( 2.1 ): the starting dosage is 6 mg/kg three times daily (18 mg/kg/day) the maximum dosage is 21 mg/kg three times daily (63 mg/kg/day). Dosage for patients weighing over 28 kg ( 2.1 ): the starting dosage is 150 mg three times daily (450 mg daily) the maximum dosage is 600 mg three times daily (1800 mg daily). Patients with severe hepatic impairment: see full prescribing information for dosage recommendation. ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}